Anna Galkin

1.4k total citations
28 papers, 1.1k citations indexed

About

Anna Galkin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Anna Galkin has authored 28 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Anna Galkin's work include Immune cells in cancer (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Analytical Chemistry and Chromatography (3 papers). Anna Galkin is often cited by papers focused on Immune cells in cancer (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Analytical Chemistry and Chromatography (3 papers). Anna Galkin collaborates with scholars based in United States, Finland and Norway. Anna Galkin's co-authors include Pia Vuorela, Leena Laitinen, Heikki Vuorela, Päivi Tammela, Peter G. Schultz, Adyary Fallarero, David B. Agus, Tami Hood, Nanxin Li and Yi Liu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Circulation and Journal of Clinical Oncology.

In The Last Decade

Anna Galkin

23 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Galkin United States 15 493 252 228 161 154 28 1.1k
Indu Parmar Canada 8 648 1.3× 252 1.0× 113 0.5× 50 0.3× 100 0.6× 12 1.2k
Chang-Mo Kang South Korea 13 887 1.8× 242 1.0× 72 0.3× 92 0.6× 118 0.8× 18 1.3k
Janis Fleming United Kingdom 22 768 1.6× 205 0.8× 197 0.9× 99 0.6× 53 0.3× 31 1.4k
Kun‐Hung Shen Taiwan 19 531 1.1× 209 0.8× 115 0.5× 145 0.9× 46 0.3× 35 1.1k
Andrean L. Simons United States 22 807 1.6× 349 1.4× 123 0.5× 215 1.3× 83 0.5× 34 1.5k
Rit Vatsyayan United States 22 634 1.3× 178 0.7× 81 0.4× 77 0.5× 68 0.4× 33 1.1k
Zebo Jiang China 23 771 1.6× 341 1.4× 216 0.9× 236 1.5× 43 0.3× 52 1.5k
Shuwen Yu China 18 670 1.4× 218 0.9× 98 0.4× 299 1.9× 57 0.4× 49 1.4k
Jung-A Choi South Korea 13 582 1.2× 190 0.8× 53 0.2× 123 0.8× 109 0.7× 22 1000
Giuseppa Augello Italy 21 529 1.1× 165 0.7× 84 0.4× 107 0.7× 73 0.5× 35 1.0k

Countries citing papers authored by Anna Galkin

Since Specialization
Citations

This map shows the geographic impact of Anna Galkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Galkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Galkin more than expected).

Fields of papers citing papers by Anna Galkin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Galkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Galkin. The network helps show where Anna Galkin may publish in the future.

Co-authorship network of co-authors of Anna Galkin

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Galkin. A scholar is included among the top collaborators of Anna Galkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Galkin. Anna Galkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Galkin, Anna, et al.. (2024). Evaluation of the efficacy of Vesusten® in patients with overactive bladder and chronic recurrent cystitis. SHILAP Revista de lepidopterología. 12(3). 36–45.
2.
Liu, Xiuting, Graham D. Hogg, Chong Zuo, et al.. (2023). Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity. Cancer Cell. 41(6). 1073–1090.e12. 53 indexed citations
3.
Galkin, Anna, Ravikumar Sitapara, Bryan Clemons, et al.. (2022). Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension. European Respiratory Journal. 60(6). 2102356–2102356. 49 indexed citations
4.
Rasco, Drew, Johanna C. Bendell, Andrea Wang‐Gillam, et al.. (2020). A phase I/II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36).. Journal of Clinical Oncology. 38(15_suppl). 3085–3085. 7 indexed citations
5.
6.
Galkin, Anna, et al.. (2019). Abstract 11102: Gb002, A Novel Inhaled Pdgfr Kinase Inhibitor, Demonstrates Efficacy in the Su5416 Hypoxia Rat Model of Pulmonary Arterial Hypertension (pah). Circulation. 4 indexed citations
7.
Galkin, Anna, et al.. (2014). RESULTS OF A GOAL-ORIENTED PROSTATE CANCER SCREENING PROGRAM IN THE PENZA REGION. SHILAP Revista de lepidopterología.
8.
Hu, Yue, Anna Galkin, Chunlei Wu, Venkateshwar A. Reddy, & Andrew I. Su. (2011). CAFET Algorithm Reveals Wnt/PCP Signature in Lung Squamous Cell Carcinoma. PLoS ONE. 6(10). e25807–e25807. 5 indexed citations
9.
Galkin, Anna, Adyary Fallarero, & Pia Vuorela. (2009). Coumarins permeability in Caco-2 cell model. Journal of Pharmacy and Pharmacology. 61(2). 177–184. 15 indexed citations
10.
Galkin, Anna, Adyary Fallarero, & Pia Vuorela. (2009). Coumarins permeability in Caco-2 cell model. Journal of Pharmacy and Pharmacology. 61(2). 177–184. 19 indexed citations
11.
Fallarero, Adyary, Sandeep Gupta, Pétra Blom, et al.. (2008). Inhibition of acetylcholinesterase by coumarins: The case of coumarin 106. Pharmacological Research. 58(3-4). 215–221. 69 indexed citations
12.
Galkin, Anna, et al.. (2008). Development of an automated 7-day 96-well Caco-2 cell culture model.. PubMed. 63(6). 464–9. 11 indexed citations
13.
Galkin, Anna, Anu Surakka, Gustav Boije af Gennäs, et al.. (2008). Hydrophobic derivatives of 5‐(hydroxymethyl)isophthalic acid that selectively induce apoptosis in leukemia cells but not in fibroblasts. Drug Development Research. 69(4). 185–195. 1 indexed citations
14.
Galkin, Anna, Moshe Finel, Kaija H. Valkonen, et al.. (2007). Transport properties of bovine and reindeer β-lactoglobulin in the Caco-2 cell model. International Journal of Pharmaceutics. 347(1-2). 1–8. 12 indexed citations
15.
Galkin, Anna, Sung Joon Kim, Tami Hood, et al.. (2006). Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proceedings of the National Academy of Sciences. 104(1). 270–275. 289 indexed citations
16.
Shazer, Ronald, Anjali Jain, Anna Galkin, et al.. (2005). Raloxifene, an oestrogen‐receptor‐β‐targeted therapy, inhibits androgen‐independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. British Journal of Urology. 97(4). 691–697. 37 indexed citations
17.
Vuorela, Satu, Maarit Karonen, Riina Nieminen, et al.. (2005). Preclinical Evaluation of Rapeseed, Raspberry, and Pine Bark Phenolics for Health Related Effects. Journal of Agricultural and Food Chemistry. 53(15). 5922–5931. 113 indexed citations
18.
Tammela, Päivi, Leena Laitinen, Anna Galkin, et al.. (2004). Permeability characteristics and membrane affinity of flavonoids and alkyl gallates in Caco-2 cells and in phospholipid vesicles. Archives of Biochemistry and Biophysics. 425(2). 193–199. 110 indexed citations
19.
Laitinen, Leena, Päivi Tammela, Anna Galkin, et al.. (2004). Effects of Extracts of Commonly Consumed Food Supplements and Food Fractions on the Permeability of Drugs Across Caco-2 Cell Monolayers. Pharmaceutical Research. 21(10). 1904–1916. 32 indexed citations
20.
Galkin, Anna, Lynne Mullen, William D. Fox, et al.. (2004). CVS‐3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. The Prostate. 61(3). 228–235. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Indu Parmar Breakdown of academic impact, for papers by Chang-Mo Kang Breakdown of academic impact, for papers by Janis Fleming Breakdown of academic impact, for papers by Kun‐Hung Shen Breakdown of academic impact, for papers by Andrean L. Simons Breakdown of academic impact, for papers by Rit Vatsyayan Breakdown of academic impact, for papers by Zebo Jiang Breakdown of academic impact, for papers by Shuwen Yu Breakdown of academic impact, for papers by Jung-A Choi Breakdown of academic impact, for papers by Giuseppa Augello
Rankless by CCL
2026